BAG-1、p53在非小细胞肺癌中的表达及其与含铂方案化疗敏感性的关系  

Correlation between the expression of BAG-1, p53 and platinum-based chemotherapeutic sensitivity in NSCLC

作　　者：吴倩[1] 朱志图[1] 哈敏文[1] 

机构地区：[1]辽宁医学院附属第一医院肿瘤科,锦州121001

出　　处：《肿瘤研究与临床》2009年第1期23-25,28,共4页Cancer Research and Clinic

基　　金：辽宁省科学技术计划（2007225005-13）

摘　　要：目的检测非小细胞肺癌（NSCLC）术后患者BAG-1、p53的表达，回顾分析其与患者临床特征及含铂方案化疗敏感性的关系，进一步探讨NSCLC的铂类耐药机制。方法应用免疫组织化学的方法检测125例NSCLC术后石蜡标本中BAG-1、p53的表达，随访后进行生存预后分析。结果BAG-1、p53在NSCLC组织中存在高表达（阳性率分别为64．8％和46．7％）；BAG-1阳性、p53阴性患者具有生存优势（P〈0．05）；BAG-1、p53表达阴性患者更能在含铂方案化疗后受益（P〈0．05）。结论BAG-1、p53与铂类药物化疗敏感性相关，可能成为新型的临床预后指标，有助于肿瘤个体化治疗方案的选择。Objective To detect the expression of BAG-1 and p53 in postoperative patients paraffin section of non-small cell lung cancer （NSCLC）, and retrospectively analyze the relationships of clinical feature and platinum-based chemotherapeutic sensitivity in NSCLC, to further investigate the resistance mechanism of platinum. Methods The expression of BAG-1 and p53 was measured by immunohistochemistry in paraffin sections of 125 NSCLC postoperative patients. The existence and prognosis were analyzed after follow-up. Results BAG-1 and p53 showed high expression in NSCLC （positive rate 64.8 %, 46.7 %）; BAG-1 positive or p53 negative expression had survival advantage（P 〈0.05）; The group of BAG-1, p53 negative expression could benefit from platinum-based chemotherapy （P 〈0.05）. Conclusion Expressions of BAG-1, p53 correlates with platinum-based chemotherapeutic sensitivity, and maybe become new types of clinical prognostic indicators and contribute to individualized treatment options for NSCLC.

关 键 词：BAG-1 P53基因 癌 非小细胞肺 铂类药物 化疗敏感性 

分 类 号：R734.2[医药卫生—肿瘤]